L3VLUP
ProSign in

REGN · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

REGNVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • REGN
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterREGNVRTX
Q3 202024 holders, $17.4bn31 holders, $21.9bn
Q4 202026 holders, $15.2bn30 holders, $18.4bn
Q1 202122 holders, $13.7bn31 holders, $15.4bn
Q2 202127 holders, $15.3bn30 holders, $12.7bn
Q3 202126 holders, $15.5bn35 holders, $10.1bn
Q4 202128 holders, $16.3bn28 holders, $12.4bn
Q1 202225 holders, $19.2bn23 holders, $16.1bn
Q2 202226 holders, $16.5bn25 holders, $18.1bn
Q3 202224 holders, $19.0bn22 holders, $18.4bn
Q4 202230 holders, $20.2bn28 holders, $18.4bn
Q1 202332 holders, $22.3bn26 holders, $21.4bn
Q2 202328 holders, $18.8bn27 holders, $24.7bn
Q3 202326 holders, $21.1bn33 holders, $24.3bn
Q4 202335 holders, $21.9bn32 holders, $28.6bn
Q1 202428 holders, $23.6bn31 holders, $29.8bn
Q2 202428 holders, $25.6bn29 holders, $33.4bn
Q3 202431 holders, $25.0bn27 holders, $33.5bn
Q4 202427 holders, $13.8bn26 holders, $28.5bn
Q1 202529 holders, $12.2bn21 holders, $35.4bn
Q2 202532 holders, $9.3bn21 holders, $32.3bn
Q3 202533 holders, $10.1bn22 holders, $25.9bn
Q4 202533 holders, $16.3bn26 holders, $31.8bn
Q1 202624 holders, $15.2bn25 holders, $31.8bn
Q2 202622 holders, $10.6bn26 holders, $34.6bn
REGN

Regeneron Pharmaceuticals

Holders
32
Reported value
$9.3bn
Buyers
24
Sellers
10

Breadth +14 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
21
Reported value
$32.3bn
Buyers
11
Sellers
11

Breadth 0 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2025

Among the 38 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only REGN (17)

Acadian Asset Management LLC, Balyasny Asset Management LLC, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Eisler Capital Management Ltd, Freestone Grove Partners LP, Millennium Management LLC, Point72 Asset Management LP, Scion Asset Management LLC, Southeastern Asset Management Inc, Tudor Investment Corp, Two Sigma Advisers LP, Two Sigma Investments LP, Verition Fund Management LLC, Voloridge Investment Management LLC, Walleye Capital LLC

Only VRTX (6)

Artisan Partners LP, Baillie Gifford & Co, Janus Henderson Group Ltd, MFS Investment Management, Renaissance Technologies LLC, Wellington Management Group LLP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →